Outcomes of Bilateral Implantation of an Enhanced Monofocal Intraocular Lens

NCT ID: NCT06118944

Last Updated: 2023-11-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-11

Study Completion Date

2023-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate and compare the visual outcomes of an enhanced monofocal intraocular lens (IOL) with two different monofocal IOLs in patients scheduled for bilateral cataract surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main objective of the study is the evaluation and comparison of the clinical outcomes of three parallel groups of patients after bilateral implantation of ICB00 IOL or ZCB00 IOL or CNA0T0 IOL respectively.

The ICB00 IOL is a modified monofocal IOL. Compared to other monofocal IOLs, its modified optical design was created to provide improved intermediate vision, comparable distance vision and a profile of dysphotopsia similar to other monofocal lenses.

Considering the modified optical profile of the ICB00 IOL, the primary objective will be the evaluation of visual performance at intermediate distance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cataract

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ICB00 Group

ICB00 IOL

Group Type EXPERIMENTAL

ICB00 IOL

Intervention Type DEVICE

Bilateral implantation of ICB00 IOL

ZCB00 Group

ZCB00 IOL

Group Type ACTIVE_COMPARATOR

ZCB00 IOL

Intervention Type DEVICE

Bilateral implantation of ZCB00 IOL

CNA0T0 Group

CNA0T0 IOL

Group Type ACTIVE_COMPARATOR

CNA0T0 IOL

Intervention Type DEVICE

Bilateral implantation of CNA0T0 IOL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ICB00 IOL

Bilateral implantation of ICB00 IOL

Intervention Type DEVICE

ZCB00 IOL

Bilateral implantation of ZCB00 IOL

Intervention Type DEVICE

CNA0T0 IOL

Bilateral implantation of CNA0T0 IOL

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TECNIS EYHANCE IOL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* clinically significant bilateral cataract (BCVA \<20/40, cataract must be the primary cause of visual impairment)
* axial length between 21 and 27 mm
* the patient must be able to read, understand and provide written informed consent,
* the patient must be willing and able to comply with all study and follow-up procedures
* preoperative refractive cylinder ≤ 0.75 D

Exclusion Criteria

* anterior segment pathology that could significantly affect results (e.g., chronic uveitis, iritis, corneal dystrophy, keratoconus)
* diabetic retinopathy
* uncontrolled glaucoma and/or intraocular pressure IOP\> 24 mmHg
* all types of infections (acute eye disease, external/internal infection, systemic infection)
* traumatic cataract
* pupillary abnormalities including aniridia and/or pupil diameter in mesopic conditions in distance vision ≤ 2.5 mm and ≥ 6 mm
* microphthalmia
* amblyopia
* degenerative visual disorders (for example macular degeneration, optic nerve atrophy or retinal disorders)
* previous intraocular and corneal surgery
* systemic or ocular pharmacotherapy, which may impact visual acuity and/or cause floppy iris syndrome and/or insufficient dilation in the opinion of the investigator
* patients who are unable to fixate for a prolonged time (e.g. strabismus, nystagmus)
* period of pregnancy or breastfeeding for female patients
Minimum Eligible Age

50 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Trieste

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Daniele Tognetto

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Daniele Tognetto, MD

Role: PRINCIPAL_INVESTIGATOR

University of Trieste

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Eye Clinic of Trieste

Trieste, Friuli Venezia Giulia, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

References

Explore related publications, articles, or registry entries linked to this study.

Lundstrom M, Behndig A, Kugelberg M, Montan P, Stenevi U, Pesudovs K. The outcome of cataract surgery measured with the Catquest-9SF. Acta Ophthalmol. 2011 Dec;89(8):718-23. doi: 10.1111/j.1755-3768.2009.01801.x. Epub 2009 Dec 21.

Reference Type BACKGROUND
PMID: 20039853 (View on PubMed)

Ribeiro F, Cochener B, Kohnen T, Mencucci R, Katz G, Lundstrom M, Casanovas AS, Hewlett D. Definition and clinical relevance of the concept of functional vision in cataract surgery ESCRS Position Statement on Intermediate Vision: ESCRS Functional Vision Working Group. J Cataract Refract Surg. 2020 Feb;46 Suppl 1:S1-S3. doi: 10.1097/j.jcrs.0000000000000096. No abstract available.

Reference Type BACKGROUND
PMID: 32126025 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

202_2019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.